Long-acting beta 2 -agonists (LABA) are the preferred add-on treatment for children with asthma whose symptoms are not well controlled on inhaled corticosteroids (ICS). The US Food and Drug Administration has issued a 'black box' warning for LABA in asthma, and now recommends that they be used "for the shortest duration of time required to achieve control of asthma symptoms and discontinued, if possible, once asthma control is achieved".
Objectives
To compare the effect on asthma control and adverse effects of stepping down to inhaled corticosteroids (ICS)-only therapy versus continuing ICS plus LABA in children whose asthma is well controlled on combined ICS and LABA therapy.
Search methods
We searched the Cochrane Airways Group Specialised Register, and also searched www.ClinicalTrials.gov, www.who.int/ictrp/en/, reference lists of primary studies and existing reviews, and manufacturers' trial registries (GlaxoSmithKline and AstraZeneca). We searched all databases from their inception to the present, and imposed no restriction on language of publication. The most recent search was done in April 2015.
Selection criteria
We looked for parallel randomised controlled trials of at least eight weeks' duration, available as published full text, abstract only, or unpublished data. We excluded studies including participants with other chronic respiratory comorbidities (for example bronchiectasis).
We looked for studies in which children (18 years or younger) whose asthma was well controlled on any dose of ICS and LABA combination therapy were randomised to: a) step-down therapy to ICS alone or b) continued use of ICS and LABA.
We included any dose of LABA (formoterol, salmeterol, vilanterol) and any dose of ICS (beclomethasone, budesonide, ciclesonide, mometasone, flunisolide, fluticasone propionate, fluticasone furoate, triamcinolone) delivered in a combination inhaler or in separate inhalers.
Data collection and analysis
Two review authors independently screened all records identified in the searches. We used a data extraction tool in Microsoft Excel to manage searches and document reasons for inclusion and exclusion, and to extract descriptive and numerical data from trials meeting the inclusion criteria.
The prespecified primary outcomes were exacerbations requiring oral steroids, asthma control, and all-cause serious adverse events.
Main results
Despite conducting extensive searches of electronic databases, trial registries and manufacturers' websites we identified no trials matching the inclusion criteria.
After removing duplicates, we screened 1031 abstracts, and assessed 43 full-text articles for inclusion. We identified several adult studies, which will be summarised in a separate review (Ahmad 2014) . The most common reasons for exclusion after viewing full texts were 'wrong comparison' (n = 22) and 'adult population' (n = 18).
Some adult studies recruited adolescents from age 15, but none reported data separately for those under 18.
Authors' conclusions
There is currently no evidence from randomised trials to inform the discontinuation of LABAs in children once asthma control is achieved with ICS plus LABA. It is disappointing that such an important issue has not been studied, and a randomised double-blind trial recruiting children who are controlled on ICS plus LABA is warranted. The study should be large enough to assess children of different ages, and to measure the important safety and efficacy outcomes suggested in this review over at least six months.
The only randomised evidence for stopping LABA has been conducted in adults; it will be summarised in a separate review.
P L A I N L A N G U A G E S U M M A R Y
Stopping long-acting beta 2 -agonists for children well controlled on combination therapy
Background
Asthma is the most common long-term medical condition in children. Poorly controlled asthma often leads to flare-ups that require extra treatment, hospital stays, or treatment in the emergency department.
Long-acting beta 2 -agonists (LABA) are an inhaled treatment that can be added to inhaled corticosteroids (ICS) for children with asthma whose symptoms are not well controlled on ICS alone. The US Food and Drug Administration issued a warning for the use of LABA in asthma after serious safety concerns emerged, and now recommends that they be used for the shortest time possible, and stopped when the child's asthma improves.
Review question
We looked for studies comparing a group of children who stopped taking their LABA with a group who continued taking ICS plus LABA. We were mainly interested in whether there is an effect on asthma control and side effects of stopping LABA.
Studies had to be at least eight weeks' long and include children whose asthma was well controlled on any dose of ICS plus LABA.
Two review authors independently screened all records found in the searches, which were done in April 2015.
Results
We found no studies matching the criteria above.
We screened 1031 records and read the full text of 43 articles we thought looked relevant, but could include none. We found several adult studies, which will be summarised in a separate review (Ahmad 2014).
Some adult studies included adolescents from age 15, but none reported data separately for those under 18.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Stopping long-acting beta 2 -agonists (LABA) compared with continuing inhaled corticosteroids ( 
Description of the condition
Asthma is a long-term respiratory condition that causes difficulty breathing due to narrowing of the airways, thickening of the airway walls, and mucus buildup. Symptoms include wheezing, shortness of breath, chest tightness, and cough that vary over time in their occurrence, frequency, and intensity (GINA 2014) . Asthma is the most common chronic medical condition among children and is one of the most common causes of hospitalisation and medical visits in children (PHAC 2007) . The condition frequently goes undiagnosed and untreated, and the direct treatment costs together with indirect costs associated with lost productivity are among the highest for non-communicable diseases (Global Asthma Report 2011). Recent estimates suggest that 235 million people are affected worldwide, and this figure continues to rise in low-and middle-income countries (Global Asthma Report 2011). Prevalence has been linked to various factors including air pollution, tobacco legislation, diet, and prevalence of other atopic diseases (Anderson 2005) . The two main aims of asthma treatment are daily control of symptoms and prevention of asthma attacks, or 'exacerbations'. These can usually be achieved in progressive treatment 'steps', depending on the severity and frequency of symptoms (Australian Asthma Handbook 2014; BTS/SIGN 2012; GINA 2014; NAEPP 2007) . Many children with asthma have intermittent symptoms that can be managed with as-needed medications (for example salbutamol), but some require regular treatment with inhaled corticosteroids (ICS) alone or in combination with other longer-acting bronchodilator medications (GINA 2009; GINA 2014 
Description of the intervention
The initial starting therapy for asthma is as-needed reliever (bronchodilator) inhalers such as salbutamol or terbutaline; this is commonly referred to as step 1 therapy. ICS is the preventer therapy primarily recommended for people with persistent asthma who do not gain sufficient control from as-needed reliever medications; this is step 2 therapy ( In 2010, the US Food and Drug Administration (FDA) issued a 'black box' warning for LABA, the strictest warning put on the labelling of prescription drugs when there is reasonable evidence of an association with a serious hazard. The warning was issued after the FDA's analyses of clinical trials showed an "increased risk of severe worsening of asthma symptoms, leading to hospitalisation in both children and adults and death in some patients with asthma" (FDA 2010) . Alongside the existing safety recommendations, the FDA has since required that manufacturers' labels state that LABA should only be used "for the shortest duration of time required to achieve control of asthma symptoms and discontinued, if possible, once asthma control is achieved". The FDA has since mandated large-scale clinical trials to assess the risks associated with LABA, which are currently under way, including a trial in children (NCT01462344). Other reviews including meta-analysis of non-randomised trials have suggested that the risks of LABA may have been overstated and that the benefits outweigh the risks for the majority of patients, perhaps because several older studies have allowed the use of LABA as monotherapy (Hernández 2014; Oppenheimer 2008 ). This field of thought suggests that a blanket warning for LABA may actually be harmful to patients who are well controlled on ICS plus LABA, and that research should focus on identifying the subset of patients who might be at risk.
How the intervention might work
ICS reduce mucus buildup and exacerbations by reducing inflammation in the airways (Barnes 1993); they can be taken once (fluticasone furoate) or twice (beclomethasone, budesonide, fluticasone propionate) daily. LABA act as a bronchodilator by relaxing bronchial wall smooth muscle and can also be taken once (vilanterol) or twice (formoterol, salmeterol) daily (Nelson 1995) . The use of LABA and ICS in combination can allow for lower steroid doses to be used, which is important to minimise side effects of steroid use in childhood such as growth suppression (Pruteanu 2014; Zhang 2014) . However, beta 2 -agonists carry their own risks, and there has been much debate regarding the possible causal links between their use and increased mortality and morbidity (Cates 2012a; Tattersfield 2006) . Theories of beta 2 -agonist-related death and adverse events include direct toxicity of the drugs themselves, in particular their cardiac effects(Brown 1983); reduced response to beta 2 -agonists over time causing a gradual worsening of disease (Lipworth 1997); and delay in receiving medical help due to the masking of underlying inflammation, known as the delay hypothesis (Bijl-Hofland 2001) . It has also been suggested that the delay hypothesis is linked to a reduction in compliance with appropriate ICS treatment (Johnston 2009), although this is less of an issue since the introduction of combination inhalers. Confounding by severity, in the sense that people with more severe disease are likely to be taking LABA, has now been dismissed, since it cannot explain the overall increase in mortality in the 1960s and 1970s and evidence from large case-control studies of beta 2 -agonists (Crane 1989). (Spycher 2010) . There are also challenges associated with diagnosis, monitoring tests, and taking medications that are specific to younger people, which warrant addressing the two populations separately.
Why it is important to do this review

O B J E C T I V E S
To compare the effect on asthma control and adverse effects of stepping down to ICS-only therapy versus continuing ICS plus LABA in children whose asthma is well controlled on combined ICS plus LABA therapy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We were interested in parallel randomised controlled trials (RCTs) of at least eight weeks' duration. We included studies reported as full text, those published as abstract only, and unpublished data. We did not include cross-over trials, as they were not suitable for the assessment of long-term outcomes.
Types of participants
We looked for studies of children aged 17 or younger whose asthma was well controlled with maintenance LABA and ICS. We prespecified that participants' asthma control should be classified according to prespecified criteria, for example below a score of 1.5 on the Asthma Control Questionnaire or the criteria for control described in GINA 2014 guidelines (that is daytime symptoms twice or less per week, need for rescue inhaler twice or less per week, no nocturnal symptoms, and no limitation to daily activities). If studies included both children and adults, we would only have included the subset of relevant participants if the study authors had been able to provide disaggregated data for participants who fit the inclusion criteria. We excluded studies including participants with other chronic respiratory comorbidities (for example bronchiectasis).
Types of interventions
We looked for studies in which children whose asthma was well controlled on any dose of ICS plus LABA combination therapy were randomised to step-down therapy to ICS alone (continued at the same dose received prior to randomisation) versus continued use of ICS and LABA (any preparation at the same dose received prior to randomisation). We included any dose of LABA (formoterol, salmeterol, vilanterol) and any dose of ICS (beclomethasone, budesonide, ciclesonide, mometasone, flunisolide, fluticasone propionate, fluticasone furoate, triamcinolone) delivered in a combination inhaler or in separate inhalers. We included studies that gave a different ICS in the intervention group, provided it was at the same beclomethasone dipropionate equivalent dose as the ICS received prior to stopping LABA, as this may reflect what happens in practice (for example replacing salmeterol/fluticasone with beclomethasone). One possible treatment strategy in asthma is to reduce the dose of both LABA and ICS concurrently once asthma control has been achieved (rather than stopping LABA); however, we did not include studies addressing the effect of this intervention, as this is a separate clinical question. We included trials that allowed short-acting reliever medications, provided they were not part of the randomised treatment.
Types of outcome measures
Primary outcomes 1. Exacerbations requiring systemic corticosteroids 2. Asthma control* (measured on a validated scale, e.g. Asthma Control Questionnaire) 3. Serious adverse events (all cause)
We chose the primary outcomes to represent an important measure of resource use, a patient-important outcome, and a measure of safety.
Secondary outcomes
1. Quality of life* (measured on a validated scale, e.g. Asthma Quality of Life Questionnaire) 2. Exacerbations requiring hospitalisation or emergency department (ED) visit 3. Adverse events (all cause) 4. Withdrawals Reporting one or more of the outcomes listed here in the trial was not an inclusion criterion for the review. *If more than one scale measuring the same construct was reported within a study, or if different scales were used across studies, we planned to analyse them using standardised mean difference. If trials reported exacerbations as a composite that was not listed (for example hospitalisation or ED visit or systemic corticosteroids), we planned to analyse these separately. If we identified any economic evaluations based on RCTs that make the comparison of interest in the main search, we summarised them narratively to supplement the main systematic review of effects.
Search methods for identification of studies Electronic searches
We identified trials from the Cochrane Airways Group's Specialised Register (CAGR), which is maintained by the Trials Search Co-ordinator for the Group. The CAGR contains trial reports identified through systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and PsycINFO, and handsearching of respiratory journals and meeting abstracts (see Appendix 1 for further details). We searched all records in the CAGR using the search strategy in Appendix 2.
We also conducted searches of ClinicalTrials.gov (www.ClinicalTrials.gov), the World Health Organization (WHO) trials portal (www.who.int/ictrp/ en/), and manufacturers' trial registries (GlaxoSmithKline and AstraZeneca). We searched all databases from their inception to April 2015, and imposed no restriction on language of publication.
Searching other resources
We checked reference lists of any relevant primary studies and review articles for additional references. We searched relevant manufacturers' websites for trial information. If included studies were found, we searched for errata or retractions published in full text on PubMed (www.ncbi.nlm.nih.gov/ pubmed).
Data collection and analysis
The following sections detail the methods we planned to use had we identified any included studies. With the exception of 'Selection of studies', we could not carry out any of the planned methods of data extraction, 'Risk of bias' assessment, and analysis for this version, but have left them intact for updates of the review in case future trials are identified.
Selection of studies
One review author (KK) and the author of the equivalent adult review (SA) independently screened titles and abstracts identified by the searches for inclusion in the review. We coded results as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We obtained the full-text study reports or publications, and two review authors (KK and SA or SB) independently screened the fulltexts to identify studies for inclusion. We identified and recorded reasons for exclusion of the ineligible studies, resolving any disagreements through discussion or by consulting a third person (SA or SB). We identified and excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (Figure 1 ) and 'Characteristics of excluded studies' table. 
Data extraction and management
If we can include studies in future updates, we will use a Microsoft Excel data collection form for study characteristics and outcome data that has been piloted on previous reviews. One review author (KK) will extract the following study characteristics from included studies.
1. Methods: study design, total duration of study, details of any 'run in' period, number of study centres and location, study setting, withdrawals, and date of study 2. Participants: N, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, and exclusion criteria 3. Interventions: intervention, comparison, concomitant medications, and excluded medications 4. Outcomes: primary and secondary outcomes specified and collected, and time points reported 5. Notes: funding for trial and notable conflicts of interest of trial authors Two review authors (KK and SB) will independently extract outcome data from included studies, noting in the 'Characteristics of included studies' table if outcome data were not reported in a usable way. We will resolve any disagreements by consensus or by involving a third person (SA). One review author (KK) will transfer data into the RevMan (Review Manager 2014) file, doublechecking that data are entered correctly by comparing the data presented in the systematic review with the study reports. A second review author (SB) will spot-check study characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (KK and SB) will independently assess the risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011), resolving any disagreements by discussion or by involving a third person (SA). We will assess the risk of bias according to the following domains:
1. Random sequence generation 2. Allocation concealment 3. Blinding of participants and personnel 4. Blinding of outcome assessment 5. Incomplete outcome data 6. Selective outcome reporting 7. Other bias We will grade each potential source of bias as high, low, or unclear and provide a quote from the study report together with a justification for our judgement in the 'Risk of bias' table. We will summarise the 'Risk of bias' judgements across different studies for each of the domains listed. We will consider blinding separately for different key outcomes where necessary (for example for unblinded outcome assessment, risk of bias for all-cause mortality may be very different than for a patient-reported pain scale). Where information on risk of bias is related to unpublished data or correspondence with a study author, we will note this in the 'Risk of bias' table.
Where there are uncertainties due to insufficient reporting, we will contact the study author or sponsor for additional information. When considering treatment effects, we will take into account the risk of bias for the studies that contributed to that outcome.
Assessment of bias in conducting the systematic review
Where possible, we conducted the review according to this published protocol and have reported any deviations from it in the 'Differences between protocol and review' section of the systematic review.
Measures of treatment effect
We will follow the methods below for future updates of this review if we identify randomised trials. We will analyse dichotomous data as odds ratios and continuous data as mean difference or standardised mean difference. We will enter data presented as a scale with a consistent direction of effect and narratively describe skewed data reported as medians and interquartile ranges. We will undertake meta-analyses only where this is meaningful, that is if the treatments, participants, and the underlying clinical question are similar enough for pooling to make sense. Where multiple trial arms are reported in a single trial, we will include only the relevant arms. If two comparisons (for example drug A versus placebo and drug B versus placebo) were combined in the same meta-analysis, we will half the control group to avoid double-counting. If change from baseline and endpoint scores are available for continuous data, we will use change from baseline unless the majority of studies report endpoint scores. If a study reports outcomes at multiple time points, we will use the end-of-study measurement. When an analysis using only participants who completed the trial and an analysis that imputed data for participants who were randomised but did not provide endpoint data (for example last observation carried forward) are both available, we will use the latter.
Unit of analysis issues
For dichotomous outcomes, we will use participants rather than events as the unit of analysis (that is number of children admitted to hospital rather than number of admissions per child). However, if exacerbations are reported as rate ratios, we will also analyse them on this basis.
Dealing with missing data
If we can include studies in future updates, we will contact investigators or study sponsors to verify key study characteristics and obtain missing numerical outcome data where possible (for example when we identify a study as abstract only). Where this is not possible, and the missing data are thought to introduce serious bias, we will explore the impact of including such studies on the overall assessment of results by a sensitivity analysis.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the trials in each analysis. If we identify substantial heterogeneity, we will report it and explore possible causes by prespecified subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and examine a funnel plot to explore possible small-study and publication biases. We will consider the impact of unpublished trials in the GRADE ratings for each outcome.
Data synthesis
If we can include studies in future updates, we will use a randomeffects model for all analyses, as we expect variation in effects due to differences in study populations and methods. We will perform sensitivity analyses with a fixed-effect model.
'Summary of findings' table
While there were no included studies, we created a Summary of findings for the main comparison to illustrate the lack of evidence for the seven prespecified outcomes. If we can include studies in future updates, we will present the pooled analysis in each case, and note any significant differences between subgroups in the comments column. We will use the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies that contribute data to the meta-analyses for the prespecified outcomes. We will use methods and recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions using GRADEpro software (Higgins 2011). We will justify all decisions to down-or upgrade the quality of studies using footnotes, and we will make comments to aid the reader's understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
If we identify trials in future updates of this review, we will carry out the following subgroup analyses for the primary outcomes, using the formal test for subgroup differences in Review Manager 2014:
1. Mean steroid dose (defined as low, medium, and high cutoffs according to GINA 2014) 2. Type of inhaler used in the comparison group (ICS plus LABA combination inhaler versus separate inhalers) 3. Type and dose of LABA being stopped (formoterol, salmeterol, vilanterol) Mean steroid dose of the population in each study may reflect differences in disease severity and may have an effect on outcomes after stopping LABA therapy. We will use the boundaries for low, medium, and high dose (ex-actuator) described in GINA 2014. Participants using combination inhalers might be less likely to experience potential adverse effects of LABA treatment, since there is no danger of taking the LABA inhaler without ICS. Combination inhalers may also be associated with generally better compliance with treatment. There may be differences in stopping different types of LABA due to their different pharmacological properties and durations of action.
Sensitivity analysis
We will carry out the following sensitivity analyses for the primary analyses, by excluding the following:
1. Studies at high risk of bias for blinding 2. Unpublished data (i.e. no peer-reviewed full paper available)
R E S U L T S Description of studies
Results of the search
We retrieved 400 records in the main database search, and searches of the additional resources (clinicaltrials.gov, WHO trials portal, reference lists, and drug company registries) returned a total of 634 records. After removing duplicates, we screened 1031 references. We excluded 988 from the title and abstracts alone. We assessed 43 full-text articles (belonging to 23 studies) for inclusion in either this review or the equivalent adult review, which is being produced in parallel. Of these, 22 made the wrong comparison, 16 were adult studies and were included in the respective review, and 4 were classified as ongoing studies or studies awaiting classification in the adult review. The one remaining study was a single-group observational study.
Included studies
No studies met the inclusion criteria.
Excluded studies
We excluded 23 studies (44 citations), mostly because the comparison was incorrect (n = 22) or an adult population was studied (n = 18). Studies were excluded due to wrong comparison usually because they tested ICS plus LABA against LABA, but were not assessing the question of stopping LABA in a well-controlled population.
Of the studies excluded due to the population age but meeting all other inclusion criteria, several included adolescent participants (from 15 or 16 years of age) but did not report data separately for those under 18 (Berger 2010; GSK SAS40037; Koenig 2008). We excluded three records because their study design did not meet the inclusion criteria: one adult cross-over study with two associated citations and one study asking the right clinical question in children using a single-group observational design (GSK SMS30046; NTR2045). We identified one other study recruiting adults and adolescents from age 12 and with a planned enrolment of 450 on clinicaltrials.gov and recorded it as an ongoing study (NCT01437995). We hope we can obtain disaggregated data for the adolescents in this study when the results are published.
Risk of bias in included studies
There were no included studies to assess for risk of bias.
Effects of interventions
See: Summary of findings for the main comparison There were no effects of interventions as no randomised trials met the inclusion criteria.
D I S C U S S I O N Summary of main results
We conducted extensive searches for trials that randomised children with well-controlled asthma to either stop their LABA or to continue taking combination ICS plus LABA. Despite conducting extensive additional searches, we identified no trials matching the inclusion criteria. After removing duplicates, we screened 1031 abstracts and assessed 43 full-text articles for inclusion. We identified several adult studies, which have been summarised in a separate review. The most common reason for exclusion after viewing full-texts were 'wrong comparison' and 'adult population'. Of the studies excluded due to the population age but meeting all other inclusion criteria, several included adolescent participants, but did not report data separately for those under 18 (Berger 2010; GSK SAS40037; Koenig 2008) . One study asking the right clinical question in children was identified on the WHO trials portal, but it was a single-group observational design (NTR2045). We identified one other study recruiting adults and adolescents from age 12 and with a planned enrolment of 450 on clinicaltrials.gov and recorded it as an ongoing study (NCT01437995). We hope we can obtain disaggregated data for the adolescents in this study when the results are published.
Overall completeness and applicability of evidence
We identified no trials making the specified comparison in children, which represents an important evidence gap considering the recommendations to stop LABA once control is achieved. It is not clear why this important issue has not been addressed in randomised trials, particularly as several have been conducted in adults. Since we do not know how stopping LABA affects symptom control or the likelihood of adverse outcomes in children, it would be ethical to randomise children to stop or continue LABA treatment. Randomised, double-blinded evidence from trials of at least six months may prevent future adverse events and poor asthma control by informing clinicians of the benefits and harms of stopping LABA relative to continuing. It is likely that future updates of this review will include data from ongoing trials conducted in populations of adults and adolescents with asthma. This evidence, if disaggregated data can be obtained, will provide important information regarding the applicability of adult evidence to younger populations. However, no published or ongoing trials have yet included children younger than age 12, and there may be different safety issues in this younger group of people with asthma.
Quality of the evidence
We excluded no trials in this review, but we conducted comprehensive searches that two review authors sifted independently. We excluded no trials for not meeting our inclusion criteria relating to duration or comedications, and there were no disagreements between review authors over their decisions to exclude. In line with Cochrane methods, we excluded no trials on the basis of language, publication status, or the outcomes reported, so we are confident that we would have identified and included any relevant randomised evidence.
Potential biases in the review process
The Cochrane Airways Group's Trials Search Co-ordinator designed and conducted the main electronic search, and two review authors discussed and sifted in duplicate additional searches. A paediatrician (SB) with expert knowledge in the area reviewed the potentially relevant records. We did not attempt to obtain disaggregated data from the three adult trials that met the inclusion criteria and included adolescents between the age of 15 and 18. Since 15 and 16 were the lower age limits in these trials, and the mean ages were between 38 and 41, we concluded that the number of adolescent participants would be small and not necessarily representative of children and adolescents in general.
Agreements and disagreements with other studies or reviews
Two systematic reviews have assessed this question, but neither were able to comment specifically on evidence for adolescents and children. While one non-Cochrane review looked for studies in adults and children (Brozek 2012) , and a Cochrane review looked solely for adult studies (Ahmad 2014), the two reviews included the same five studies in meta-analysis and reached similar conclusions. Brozek 2012 noted the lack of evidence for children and the inclusion of older children and adolescents (15 years and over) in several of the trials, but without individual participant data in larger and longer trials, it is not possible to judge whether the older children within the adult studies had different outcomes, and there is no information for younger children. Both reviews concluded that the evidence for adults and older children suggests a clear loss of symptom control after stopping LABA on several measures. Both reviews suggested that even the evidence base for adults and older children is incomplete; there were infrequent events for some of the most important outcomes (for example exacerbations requiring hospital admission, serious adverse events, and mortality), a small number of trials contributing to several of the meta-analyses, and relatively short follow-up times. This paucity of evidence also precluded any meaningful subgroup analyses to explore possible effect modifiers such as ICS dose and type of LABA. There is a total lack of information for children under 15 years of age.
A U T H O R S ' C O N C L U S I O N S Implications for practice
There is currently no evidence from randomised trials to inform LABA discontinuation in children once asthma control is achieved with ICS plus LABA.
The only randomised evidence for stopping LABA has been conducted in adults, and will be summarised in a separate review (Ahmad 2014). Evidence from an ongoing trial recruiting adults and children over age 12 may provide some initial evidence for older children.
Implications for research
A double-blind randomised trial to assess this question would help clinicians judge when it is safe and beneficial to stop LABA in children. The study should be large enough to assess children of different ages, and measure the important safety and efficacy outcomes suggested in this review over at least six months.
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NCT01437995
Trial name or title Long-acting Beta Agonist
Step Down Study (LASST) Methods 56-week, multicentre, blinded, randomised, double-masked parallel group comparative effectiveness study of approaches to stepping down therapy for people with well-controlled asthma treated with combination ICS and LABA
Participants
Inclusion Criteria: males and females aged 12-80 years with well-controlled asthma on moderate dose ICS/ LABA based on an Asthma Control Test score ≥ 20, absence of unscheduled visits or use of rescue prednisone for 4 weeks prior to enrolment and a pre-bronchodilator FEV1 ≥ 70% predicted Exclusion Criteria: chronic oral steroid therapy, hospitalisation or urgent care visit within 4 weeks of the screening visit, lung disease other than asthma including COPD, bronchiectasis, sarcoidosis, or other lung disease. Less than 10 pack/yr of tobacco use and abstinence, post-bronchodilator FEV1 < 70% predicted, near fatal asthma (intubation or ICU admission for asthma) within 2 yrs of enrolment, high risk of near fatal or fatal asthma, history of known premature birth less than 33 weeks or any significant level of respiratory care including prolonged oxygen administration or mechanical ventilation during the neonatal period, unstable cardiac disease (decompensated congestive heart failure, unstable angina, recent myocardial infarction, atrial fibrillation, supraventricular or ventricular tachycardia, congenital heart disease, or severe uncontrolled hypertension), other major chronic illnesses, drug allergies, pregnancy, lactation
Interventions
Stepping down from fluticasone/salmeterol Diskus 250/50 mcg twice a day to fluticasone Diskus 250 mcg twice a day without salmeterol Outcomes Primary: Rate of treatment failures (decline in peak flow or FEV1, increased need for beta agonists, requirement for non-scheduled medical care for asthma symptoms, or prednisone taper) Secondary: Pulmonary function (morning peak expiratory flow, pre-bronchodilator FEV1), episodes of poor asthma control defined by unscheduled medical care, hospitalisation, use of oral corticosteroids and/or
